Equities
Health CareMedical Equipment and Services
  • Price (EUR)20.00
  • Today's Change0.00 / 0.00%
  • Shares traded6.09k
  • 1 Year change-27.14%
  • Beta0.7867
Data delayed at least 15 minutes, as of Mar 04 2026 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stratec SE is a Germany-based company. The Company is engaged in development and manufacture of analyzer systems, and it is also performing and managing administrative and organizational tasks for laboratory markets. Stratec is providing automation solutions and instrumentation of biochemical processes using hardware and software for in-vitro diagnostics and life science companies. It also developing and integrating instrumentation, complex consumables and software by covering virtually the entire value chain for specification, design, manufacture and approval of complex analyzer system solutions.

  • Revenue in EUR (TTM)256.91m
  • Net income in EUR15.65m
  • Incorporated2018
  • Employees1.42k
  • Location
    Stratec SeGewerbestr. 37BIRKENFELD 75217GermanyDEU
  • Phone+49 708279160
  • Fax+49 70 827916999
  • Websitehttps://www.stratec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
EKF Diagnostics Holdings PLC57.75m7.04m125.64m297.0018.741.589.942.180.01350.01350.11090.15970.62093.167.34165,745.907.985.798.776.7649.7949.4212.868.623.47--0.0152---4.592.25165.3911.163.02--
Surgical Science Sweden AB92.20m6.21m143.09m313.0023.050.360410.251.551.311.3119.4583.740.19511.747.253,170,425.001.313.301.433.5466.2867.866.7317.993.36--0.0004--12.2556.77-49.2433.7641.51--
Nyxoah SA5.64m-83.72m146.71m184.00--2.48--26.02-2.24-2.240.15091.360.04770.35432.1530,646.74-70.84-27.03-83.81-29.8164.3663.56-1,484.66-1,347.971.41--0.2934--3.98---37.08--86.96--
Stille AB52.74m5.18m151.11m220.0029.162.2918.242.876.216.2163.8078.870.55231.716.912,580,132.005.426.006.186.8450.7348.819.819.861.95-------0.407231.82-4.3146.43-2.68--
Carasent AB (publ)31.95m3.22m154.90m196.0046.101.9516.914.850.500.504.8511.800.3416--7.941,754,184.003.44--3.89--84.06--10.08------0.038--24.91--182.04------
Detection Technology Oyj-100.00bn-100.00bn156.82m497.00--2.01----------5.34----------8.02--10.04--46.64--7.502.30----61.79-6.044.37-42.04-0.892-13.111.39
Guerbet SA809.67m7.74m159.53m2.91k31.050.42282.270.1970.40640.406464.2529.850.78650.5464.90278,715.700.46190.920.60551.2078.0376.510.58731.191.031.460.517264.797.050.5853-32.61-15.50-0.8569--
Affluent Medical SA4.12m-14.74m180.10m76.00--5.67--43.74-0.3759-0.37590.10510.53650.0709--0.954159,681.16-25.40-23.76-32.61-27.591.34-226.93-358.01-1,815.40---924.300.5030------5.84------
Median Technologies SA23.31m-21.99m186.16m211.00------7.99-1.16-1.161.23-2.080.8894-12.983.9296,717.84-83.91-60.70---232.35102.73102.32-94.35-97.730.3543-26.56----3.2520.72-9.83--43.77--
Tristel Plc56.97m9.04m209.46m265.0023.405.4116.853.680.16240.16241.020.70241.122.196.48186,932.1017.829.6020.6811.0980.2780.9015.8811.043.45--0.1479127.6510.807.962.335.42-3.5918.10
Onward Medical NV1.11m-38.65m225.15m102.00--6.47--202.48-0.866-0.8660.02490.62090.0215--9.1110,901.96-74.86-55.03-92.84-61.1977.16---3,475.81-39,652.374.30-17.130.352--236.76--1.26--3.88--
Prim SA240.47m14.55m234.25m954.0014.981.769.180.97420.91760.917614.137.801.171.974.17251,008.807.096.2710.408.5038.7737.706.055.851.20144.870.139963.107.689.08-13.83-0.536613.506.35
Stratec SE256.91m15.65m243.16m1.42k15.531.017.050.94651.291.2921.1319.750.58251.325.65177,177.203.556.724.247.9629.0928.416.099.631.656.850.355237.35-4.733.764.242.35-7.49-6.51
CellaVision AB70.52m14.22m328.44m236.0023.093.9818.374.666.426.4231.8237.210.72012.026.80--14.5214.7116.2216.9668.5068.3820.1719.852.9725.880.028141.974.949.998.7811.3420.7629.67
Medistim ASA62.29m14.17m352.60m154.0024.808.4321.275.668.718.7138.2825.621.130.7979.01--25.7723.1532.3328.7481.6879.4022.7521.112.21--0.074185.5124.3814.0253.3318.07--21.67
Data as of Mar 04 2026. Currency figures normalised to Stratec Se's reporting currency: Euro EUR

Institutional shareholders

28.09%Per cent of shares held by top holders
HolderShares% Held
Brown Capital Management LLCas of 31 Dec 20251.09m8.99%
Juno Investment Partners BVas of 30 Nov 2025418.59k3.44%
Briarwood Chase Management LLCas of 13 Feb 2026414.73k3.41%
Union Investment Privatfonds GmbHas of 13 Feb 2026341.28k2.81%
Janus Henderson Investors UK Ltd.as of 31 Jan 2026304.67k2.51%
Candriam Belgium SAas of 31 Dec 2025184.05k1.51%
Invesco Advisers, Inc.as of 22 Jan 2025180.57k1.49%
UBS Asset Management Switzerland AGas of 28 Nov 2025180.00k1.48%
BNP Paribas Asset Management Europe SASas of 30 Jan 2026159.29k1.31%
Investor Asset Management BVas of 20 Feb 2026139.50k1.15%
More ▼
Data from 30 Nov 2025 - 20 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.